Hidden pancreas trouble in Crohn's patients starting biologics
NCT ID NCT03915262
First seen Jan 04, 2026 · Last updated May 16, 2026 · Updated 19 times
Summary
This study looks at how common exocrine pancreatic insufficiency (EPI) is in people with active Crohn's disease who are starting a new biologic therapy. EPI means the pancreas doesn't make enough enzymes to digest food properly. Researchers will check 50 adults at the start of treatment and again after 14 weeks to see how many have EPI, and also track nutrition and disease activity.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CROHN DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Service d'Hépato-Gastroentérologie, Centre Hospitalier Lyon-Sud, HCL
RECRUITINGPierre-Bénite, 69495, France
Contact
Contact
Contact
Contact
Contact
Contact
Conditions
Explore the condition pages connected to this study.